Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine CHMI Study
NCT02015091Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2013
- Primary completion
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Sanaria PfSPZ Vaccine in malaria (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and tolerability of PfSPZ Vaccine following multiple-dose IV administration, Safety and tolerability of PfSPZ Vaccine following multiple-dose IM administration and 1 more. Started Dec 2013; status: completed.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02015091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015091.